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ABSTRACT

The use of vaccinia virus (VACV) as a vaccine resulted in the eradication of
smallpox in 1979. Characteristics that contribute to the effectiveness of VACV as a
vaccine and viral vector include its ability to elicit strong, long-lived humoral and cellmediated immune responses as a live-replicating virus and to accept large inserts of DNA
into its genome. However, adverse events associated with its use as the smallpox vaccine
have constrained it from being more widely utilized in vaccines and therapies. We
propose to improve the safety of VACV as a live-replicating vector by using elements of
the tet operon to control transcription of VACV genes essential for virus growth. This
would allow viral replication to be regulated through the addition or removal of
tetracyclines. Seven VACV genes were tested in an attempt to control viral replication.
For each gene a different recombinant was generated in which the essential gene was
placed under the control of tet operon elements. Of the seven VACV genes tested,
recombinants utilizing the A6L, A7L, D6R, and F17R genes were successful in
regulating viral replication with tetracyclines.
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CHAPTER 1: INTRODUCTION
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1.1. VACCINIA VIRUS AND SMALLPOX
Vaccinia virus (VACV) is the prototypical member of the family Poxviridae,
genus Orthopoxvirus. This genus also includes cowpox virus, monkeypox virus, and
most notably variola virus, the causative agent of smallpox. Smallpox was an extremely
devastating disease that affected the world for thousands of years. Efforts to protect
against this disease lead to the development of vaccination. The earliest reports of
attempts to protect against smallpox come from China in the 10th century, where
variolation by insufflation was practiced (Fenner, 1988). People would be deliberately
inoculated with smallpox from the pustules of patients that had the active disease. This
practice decreased the fatality rate from 20-30% to 0.5%-2.0% (Fenner, 1988). It was not
until after 1798, when Jenner discovered that cowpox was able to protect against
smallpox, that modern vaccination practices began. Overtime VACV replaced cowpox
virus as the vaccine agent; even though the origin of VACV is uncertain, it is genetically
distinct from both variola and cowpox virus. The use of VACV as the smallpox vaccine
was eventually responsible for the eradication of smallpox, declared in 1979 by the
World Health Organization (WHO) (Wehrle, 1980).

1.2. VACCINIA VIRUS AS A VECTOR
VACV has been developed as an expression vector, allowing heterologous
(foreign) genes to be expressed by the virus. Recombinant gene expression using VACV
was first accomplished in 1982 when the herpesvirus thymidine kinase (TK) gene was
inserted into a TK- VACV strain, giving the recombinant a TK+ phenotype (Mackett, et
al., 1982, Panicali and Paoletti, 1982). The flexibility of VACV for accepting foreign
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DNA was tested by inserting 25 kb of bacteriophage λ DNA into the VACV TK gene,
thus determining that VACV is capable of forming stable, infectious, and replication
competent recombinants with as much as 25 kb of foreign DNA (Smith and Moss, 1983).
VACV expression vectors can be used to study protein structure, function, and
processing, as well as to develop recombinant vaccines where the heterologous expressed
gene is used to elicit immune responses (Carroll and Moss, 1997). The extensive
characterization of VACV, along with its ability to elicit strong humoral and cellmediated immune responses as a live replicating virus and accept large inserts of DNA
into its genome, makes it an ideal viral vector (Bennink, et al., 1984). VACV has been
successfully used in rabies and rinderpest vaccines, leading to better control of these
diseases (Slate, et al., 2009, Verardi, et al., 2002). Another feature of VACV that makes
it an appealing vector is its ability to infect a wide range of cells, including different
tumors. The immunogenicity of VACV combined with its broad tumor tissue tropism
can be used to enhance host immunity against tumor cells (Mullen and Tanabe, 2002).
This allows VACV to be used as an oncolytic vector and to be used in immunotherapies
for cancer treatment (Jager, et al., 2006, Kaufman, et al., 2004, Rochlitz, et al., 2003).
For example, VACV has been engineered to express prostate-specific antigen (PSA),
which is over expressed in prostate cancers. This VACV has proven to induce PSAspecific T cell responces and therapeutic activity. In clinical trial the therapy was
tolerated well and in 78.1% of patients the cancer did not progress (Kaufman, et al.,
2004).

3

1.3. ADVERSE EVENTS ASSOCIATED WITH THE SMALLPOX VACCINE
Although VACV is an excellent viral vector, the adverse events associated with
its use as the smallpox vaccine have constrained it from being more widely utilized as
vaccines and therapies. Adverse events associated with the smallpox vaccine fall into
three major categories according to their severity. Mild to moderate adverse events
include feeling sick enough to miss work, fever, and mild rash that resolves without
intervention. Moderate to severe adverse events include autoinoculation, generalized
vaccinia (a rash that covers the entire body but resolves without intervention), and
myopericarditis. Severe to life-threatening adverse events include eczema vaccinatum (a
severe rash on an individual with atopic dermatitis), post-vaccinial encephalitis, and
progressive vaccinia (vaccinia necrosum) which leads to skin and tissue destruction due
to uncontrolled replication of the virus in immunocompromised individuals (Fulginiti, et
al., 2003). A study of smallpox vaccine complications in 1968 surveyed 10 US states for
complications. This study found 529.2 cases of accidental implantation per million,
241.5 of generalized vaccinia, 12.3 of post-vaccinial encephalitis, and 1.5 of vaccinia
necrosum (Lane, et al., 1970). Despite these complications, vaccination efforts during
the global eradication program led the WHO to declare smallpox eradicated in 1979,
more than 30 years ago.

1.4. TREATMENT OF ADVERSE EVENTS
With the current smallpox vaccine, if adverse events occur, vaccinia
immunoglobulin (VIG) and investigative new drugs such as cidofovir are approved to
manage the complications. Although there is evidence from the smallpox eradication
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period that suggests individuals with adverse events benefit from VIG treatment, there
have been no controlled studies. Intravenous VIG (IGIV produced by Cangene and
VIGIV produced by Dynport) was licensed by the Food and Drug Administration (FDA)
for use in 2005 for the treatment of progressive vaccinia, eczema vaccinatum, severe
generalized vaccinia and extensive body surface involvement or periocular implantation
(Wittek, 2006). Side effects associated with VIG treatment, although typically mild, can
include severe events such as hypotension, renal dysfunction and aseptic meningitis
syndrome (Cono, et al., 2003). Cidofovir is only recommended to treat adverse events if
VIG treatment fails or if the patient is close to death. Side effects associated with
Cidofovir include renal toxicity, neutropenia, and metabolic acidosis. Animal studies
have also shown cidofovir to be carcinogenic (Cono, et al., 2003).

1.5. CONTRAINDICATIONS FOR SMALLPOX VACCINATION
As smallpox is no longer present in the world as a natural infection, there are
many contraindications for receiving the vaccine. These include current or past history of
eczema, acute or chronic dermatitis, being immunocompromised or immunosuppressed
(due to illness, cancer therapy, immunosuppressive treatment after transplantation, or
HIV/AIDS), heart conditions, pregnancy, or having contacts with anyone who has a
contraindication (Fulginiti, et al., 2003). The population at risk for developing adverse
events has risen since the time of the smallpox eradication program. With medical
advances in transplantation, cancer and HIV treatment there are now more people living
with compromised immune systems, a major contraindication for smallpox vaccination.
The number of people living with HIV has continued to increase as HIV treatments
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extend life and as new infections continue to occur each year. The number of people
living with HIV worldwide at the end of 2008 was estimated at 33.4 million
(UNAIDS/WHO, 2009). The prevalence of eczema has also increased since the smallpox
eradication era, being estimated to be as high as 20% in Europe, Australia, and the United
States (Brown and Reynolds, 2006). It has been estimated that 25% of the United States
population is contraindicated for smallpox vaccination (Kemper, et al., 2002). The
increasing number of people with major contraindications would greatly complicate
smallpox vaccination efforts with the standard smallpox vaccine if it needed to resume,
and it hampers the widespread use of VACV as a vaccine and therapeutic vector.

1.6. CURRENT STATUS OF SMALLPOX VACCINATION IN THE UNITED
STATES
Although smallpox is no longer a naturally occurring infection, there is still the
threat of reemergence through a bioterrorist event. Due to that threat, military personal,
first responders, and researchers working with orthopoxvirues are still vaccinated against
smallpox using VACV. However, the vaccine is not available to the general public since
it would provide little benefit and may actually cause harm (Bozzette, et al., 2003). The
United States military vaccine program has shown that careful screening and education of
the vaccine recipient lowers the occurrence of adverse events below the historical rates
from the eradication program era (Grabenstein and Winkenwerder, 2003). If smallpox
were to reemerge through a bioterrorism event, or if another orthopoxvirus emerged as a
significant human pathogen (e.g., monkeypox), mass vaccination with VACV may need
to resume either in isolated populations or entire geographical regions. Current guidelines
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state that in an emergency situation (for example the intentional release of the smallpox
virus), no absolute contraindications would exist for persons exposed to smallpox
(Centers for Disease Control and Prevention, 2001). Contraindications would be
disregarded in this setting because individuals that are at the greatest risk for serious
adverse events are also at the most risk for death from smallpox (Centers for Disease
Control and Prevention, 2001).

1.7. NEW GENERATION SMALLPOX VACCINES
As safety is the foremost priority for a vaccine, there is a need to develop safer,
new generation vaccines for smallpox. While the focus of new smallpox vaccines is on
improved safety, their efficacy must also be maintained or improved. Dryvax is a firstgeneration vaccine that was used during the United States eradication campaign of the
1970s. It is based on the New York City Board of Health (NYCBH) strain of VACV and
was produced by Wyeth Laboratories (Handley, et al., 2009). This vaccine was
propagated in the skin of calves and isolated by skin scraping (Artenstein, 2008).
ACAM2000 recently replaced Dryvax as an improved second-generation vaccine. This
vaccine was licensed for use in the United States in 2007, and is clonally derived from
the Dryvax vaccine by plaque purification. ACAM2000 is propagated in tissue culture,
decreasing the risk of contamination by microbial agents. It is also less neurovirulent
than the Dryvax vaccine (Monath, et al., 2004). ACAM2000 was able to be licensed
because it demonstrated equivalent immunogenicity to the Dryvax vaccine, which is a
requirement for new smallpox vaccines (Artenstein, 2008). Vaccination with either
Dryvax or ACAM2000 by scarification produces a scar, known as the vaccine “take”.
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There is a direct relationship between the take and protection from smallpox (Artenstein,
2008), and the take is generally considered the only known correlate of protection for
smallpox.
New generation smallpox vaccines all focus on increasing vaccine safety while
maintaining efficacy. Many new generation vaccines have taken the approach of
attenuating the vaccine virus. Such vaccines include MVA (modified vaccinia Ankara)
and NYVAC. NYVAC was developed by deleting 18 VACV genes, leaving the virus
unable to replicate in humans (Tartaglia, et al., 1992). MVA was generated by passing
VACV in chick embryo fibroblasts (>570 times) until the virus lost the ability to replicate
in most mammalian cells. This virus has been studied extensively as a safer alternative to
replication competent VACV. As MVA cannot replicate in human cells, no serious
adverse events have been associated with its use in humans. Although MVA was used
during the eradication period, it was never utilized in an area where smallpox was
endemic, and therefore the efficacy of MVA against variola has never been assessed.
While MVA is undisputedly safer than replication competent smallpox vaccines, it has
been shown to require multiple doses to achieve immunogenicity equivalent to Dryvax
(Grandpre, et al., 2009, Parrino, et al., 2007, Wyatt, et al., 2004).
Unfortunately the use of a replication deficient smallpox vaccine requiring a
multi-dose regimen is unfeasible in the event of a bioterrorist event involving smallpox.
One suggested approach for the use of MVA or other replication deficient VACVs is to
immunize before there is any risk of smallpox infection and boost with the standard
smallpox vaccine or with MVA in the event of an immediate threat (Earl, et al., 2004).
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This proposed vaccination scheme would require keeping the population vaccinated with
MVA in preparation for a possible smallpox threat.
Even with the improvements provided by ACAM2000, there is still an urgent
need to develop an even safer smallpox vaccine for the ever-increasing population with
contraindications that at a minimum retains the ability to elicit the protective immunity
that the first-generation vaccines provided.

1.8. HYPOTHESIS
The goal of increasing vaccine safety while maintaining efficacy has proven to be
difficult. The approach of attenuating VACV, while successful at minimizing adverse
events, has come at the cost of efficacy and the uncertainty of its ability to provide
protection equivalent to first-generation vaccines. In an effort to maintain vaccine
efficacy while increasing safety, I hypothesize that elements of the tet operon can be used
to control the transcription of a VACV gene essential for virus growth, thereby regulating
replication of the virus. These viruses would address the need for a safer, yet
indisputably protective, smallpox vaccine.
Regulation of an essential gene can be achieved by constitutively expressing the
TetR repressor protein within the VACV genome and incorporating a tet operator (tetO)
into the promoter of an essential gene (Figure 1-1).
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Figure 1-1. Tetracycline Induced Gene Expression in Vaccinia Virus.
Virus In the absence
of tetracycline (denoted by yellow star) TetR protein is produced and binds to the
operator sequence in the promoter for the essential VACV gene, preventing transcription.
In the presence of tetracyclines,
yclines, tetracycline binds TetR and prevents TetR from
interacting with the operator, thus allowing transcription of the essential gene.

1.9. SIGNIFICANCE OF PROPOSED WORK
The inducible VACVs generated will have many potential uses. The new
recombinant VACVs could serve as new generation smallpox vaccines that are safer and
as efficacious as ACAM2000. They could also act as new generation viral vectors for
both human and animal
nimal vaccines, and as oncolytic vectors. They would be safer not only
for the recipients of the vaccine or therapy, but also for the personnel administering the
vectors (e.g., vaccinators) and contacts of the vaccine/therapy recipients.
The inducible VAC
VACVs
Vs are excellent candidates for a new generation smallpox
vaccine. As the inducible viruses can be made utilizing the ACAM2000 vaccine strain or
another first-generation vaccine strain, the immune response that will be generated by the
inducible VACVs should
uld be extremely similar (if not identical) to the current vaccine and
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produce a “take”. These similarities would allow the vaccine to fulfill the non-inferiority
to ACAM2000 requirement for FDA licensure. If utilized as the smallpox vaccines, the
inducible VACVs could be administered to individuals whom have contacts with
contraindications. This would prevent the vaccinee from transmitting the virus to
contacts (as long as the contacts were not receiving tetracycline treatment).
This inducible form of vaccination would have been particularly useful in a case
of inadvertent inoculation that occurred in Indiana in 2007. A United States service
member received smallpox vaccination in preparation for deployment, when his
deployment was delayed he made an unplanned visit to his family. His son, who had
eczema, developed a life-threatening case of eczema vaccinatum which required
investigational antivirals (cidofovir), VIGIV, and 48 days of hospitalization to recover
(Centers for Disease Control and Prevention, 2007). If the inducible VACV had been
used, inadvertent inoculation could have been avoided, as tetracyclines would need to be
taken with the vaccine for viral replication to occur. As long as the child was not taking
tetracyclines the virus would not have been able to replicate and eczema vaccinatum
would not have developed. Since VACV is also used in cancer immunotherapy and as an
oncolytic vector in patients that can be mildly to severely immunocompromised, use of
inducible VACV vectors would greatly enhance the safety of these therapies.

1.10. INDUCIBLE VACCINIA VIRUS SYSTEMS
Two operon systems have been adapted for use in VACV, the lac operon system
and more recently the tet operon system. The lac operon system was first adapted to
VACV in 1989, when it was used to regulate the expression of an inserted β-
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galactosidase gene. The lac repressor (lacI) was inserted into the VACV genome under a
constitutive promoter and the lac operator (lacO) was inserted after a strong VACV late
promoter initiator sequence prior to the translational start site of the β-galactosidase gene.
This genetic setup made the expression of β-galactosidase dependent on the inducer
IPTG (isopropyl-β-D-thiogalactoside) (Fuerst, et al., 1989). This same lac operon setup
was later used to control the expression of the VACV p11 (F17R) gene (Zhang and Moss,
1991a). The ability to control gene expression through the addition of inducer is a
powerful method to investigate the function of individual VACV genes. The lac operon
has been utilized to investigate the function of numerous VACV genes, including p11,
early transcription factors, RNA polymerase associated protein, and membrane proteins.
The most common genetic setup using the lac operon involves the use of the
bacteriophage T7 RNA polymerase and is commonly referred to as vIT7LacO. For this
genetic arrangement, elements are typically inserted into the TK (or another nonessential)
region of the virus. The P7.5 promoter expresses the lacI gene constitutively and the
inserted bacteriophage T7 RNA polymerase gene is under the control of a strong late
promoter (e.g, P11) with a lac operator sequence inserted between the start site of the gene
and the initiator of the promoter. This causes the expression of the T7 RNA polymerase
to be inducible by IPTG. To regulate the gene of interest (originally tested with the βgalactosidase gene), it was placed under the control of a T7 promoter (sometime also
incorporating a lacO sequence), making the expression of β-galactosidase inducible by
IPTG (Alexander, et al., 1992). More recently the tet operon system has been adapted to
VACV. The tet operon was first used in VACV as an alternative to the lac operon
system to regulate the expression of the A14L gene (Traktman, et al., 2000).
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1.11. THE TETRACYCLINE OPERON
In an effort to improve the safety of VACV vectors while maintaining efficacy,
elements of the tet operon will be used to control the transcription of VACV genes
essential for virus growth, thereby regulating replication of the virus. The tet operon is
carried on transposon 10 in E. coli, conferring resistance to tetracyclines. It consists of
two genes, the resistance gene (tetA) and the repressor gene (tetR) (Postle, et al., 1984).
The tetR gene produces a repressor protein (TetR) that binds to the tet operator sequences
(tetO) that overlap tet operon promoters, thus inhibiting the transcription of the tet operon
genes. TetR binds to tetracyclines (e.g., tetracycline, doxycycline, and
anhydrotetracycline), altering its conformation so that it is unable to bind to the operator
sequences, thus allowing transcription of the operon genes (Hillen and Berens, 1994).
The two binding sites (operators) for TetR in the tet operon (O1 and O2) consist of 19 bp
sequences that bind two homodimeric molecules of TetR as a dimer. Even though O1 is a
perfect palindrome around a T/A center of symmetry and O2 is an imperfect palindrome,
TetR binds to operator O2 with three- to five-fold higher affinity than to operator O1
(Hillen and Berens, 1994).
The tet operon has been adapted to VACV where it was used to investigate the
function of A14, a membrane protein, during VACV life cycle. The O2 sequence was
inserted between the transcriptional and translational start sites of the A14L gene, and
tetracycline was able to regulate the expression of the A14L gene (Traktman, et al.,
2000). More recently, the expression of reporter genes and cytokines both in vitro and in

13

vivo were controlled using several different promoters and operator sequence
combinations (P. Oliveira-Weber et al., unpublished data; Weber, et al., 2007).

1.12. TETRACYCLINES
Tetracyclines, a group of antibacterials first used in the 1950s, includes
tetracycline, doxycycline, minocycline, and numerous others. Tetracycline antibiotic
activity results from the molecule binding to ribosomes, causing the inhibition of
bacterial protein synthesis. Tetracycline (a group 1 tetracycline) was introduced in 1950
and is less lipophilic than group 2 tetracyclines, which includes doxycycline.
Tetracycline is absorbed at 77-88% and the peak concentration in the serum (1-5 mg/l), is
reached between 2-4 h when a 250-500 mg dose is given. The serum half-life of
tetracyclines is 6-10 h. Doxycycline is thought to be almost completely absorbed when
taken orally, reaches peak concentrations by 2-3 h, and has a long half-life of
approximately 20 h (Agwuh and MacGowan, 2006). The typical tetracycline dose for
adults is 500 mg twice daily. Complications associated with treatment using tetracyclines
are generally mild and can include: photosensitivity (not typically associated with
doxycycline or minocycline), discoloration to teeth (infancy to the age of 8), nausea, and
diarrhea. Treatment with tetracyclines is not indicated for pregnant women and children
less than 8 years of age (Cunha, 2001). Tetracycline treatment is generally safe and is
utilized to treat many infections (Table 1-1).
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Table 1-1: Uses and Doses of Different Tetracyclines.
Antibiotic

Treatment

Dose

Duration

Reference

Doxycyline

Adult Early

100 mg, twice daily

14-21

(Wormser, et al.,

days

2000)

Lyme Disease
Doxycycline

Lyme Disease in

1-2 mg/kg, twice

14-21

(Wormser, et al.,

Children >8 yrs

daily (max. dose 500

days

2000)

-

(Haider and Shaw,

mg)
Doxycycline

Moderate Acne

20-100 mg, twice

2004)

daily
Tetracycline

Moderate Acne

500 mg, twice daily

-

(Haider and Shaw,
2004)

Tetracycline

Cholera

200-400 mg, daily

3-5 days

(Wallace, et al.,
1968)

1.13. VACCINIA VIRUS REPLICATION
Unlike most DNA viruses, poxviruses are unique in that they replicate in the cell
cytoplasm, instead of the nucleus. Replication can occur in the cytoplasm because the
virus encodes all proteins necessary for its replication, such as DNA and RNA
polymerases (Moss, 2007). Transcription of VACV genes occurs in three stages: early,
intermediate, and late. During each stage, proteins that allow transcription to progress to
the next stage (e.g., transcription factors) are produced. VACV promoters determine the
stage at which each gene will be transcribed. After VACV attaches to a cell, it releases
its core into the cytoplasm. The core contains all of the factors necessary for early
transcription; this allows early mRNA to be synthesized and early proteins to be
expressed. After early transcription, uncoating occurs and the viral DNA is replicated
within viral factories (granular foci within the cell that do not contain normal cellular
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organelles). Intermediate transcription then takes place using the replicated DNA as a
template. This is followed by late transcription, which produces abundant amounts of
structural proteins, as well as all of the proteins required for early transcription. Virion
morphogenesis follows, in which these proteins and the replicated DNA are packaged
into new virions. Virion morphogenesis is first evidenced by the appearance of crescentshaped membrane structures; these crescents turn into immature virions (IV), which may
contain nucleoids of electron-dense DNA (INV, immature virion with nucleoid). The IVs
continue to mature into infectious particles, either intracellular mature virions (IMVs) or
extracellular enveloped virions (EEVs). The majority of the virus particles remain as
IMVs within the cell and are thought to mediate spread between hosts, while EEVs are
released from the cell by budding and are responsible for dissemination of the virus
within the host (Moss, 2007).
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CHAPTER 2: USE OF VACCINIA VIRUS EARLY D1R GENE TO
CONTROL VIRAL REPLICATION
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2.1. INTRODUCTION
To control the replication of VACV with tetracyclines, the VACV D1R gene was
chosen to be placed under the control of tet operon elements. A comprehensive
investigation of VACV genes directly involved in virus replication led to this decision.
Candidate genes were selected based on their presumed function in the virus life cycle
(e.g., RNA and DNA polymerases, transcription factors, etc.) and on published
experimental work. A total of 16 essential candidate genes were initially identified. The
positions of these genes in the VACV genome and their upstream intergenic regions (the
region between the start site of the essential gene candidate and the end or start of the
upstream gene) were then carefully inspected to determine if it would be possible to
insert the tet operon elements without disrupting transcription of the surrounding genes.
For example, the early transcription factor large subunit (A7L) was not considered an
ideal essential gene candidate because its intergenic region contains both the promoter for
the transcription factor and a promoter for the upstream gene. Likewise, the promoter for
the RNA polymerase 22 kDa subunit gene (J4R) is located within the upstream gene.
Inserting tet operon elements before either gene would cause the transcription of both the
essential gene and the upstream gene to be affected. This initial analysis narrowed the
number of candidate genes to seven.
All candidate essential genes with appropriate intergenic regions were then further
researched to determine if they would be able to control VACV replication. B1R (a SerThr kinase), E8R (a membrane protein) and D1R (the large subunit of the capping
enzyme) were the three best essential candidate genes. Studies of E8R demonstrated only
a reduction in plaques formed by temperature sensitive- (ts) mutants and studies of B1R
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were only able to show that attempts to delete the gene were unsuccessful, suggesting
that the gene is essential to viral replication (Kato, et al., 2007, Rempel and Traktman,
1992). A study of the D1R gene done by Shatzer et al. showed that ts-mutants were
unable to generate any infectious progeny at non-permissive temperatures, indicating that
the gene is essential for viral replication (Shatzer, et al., 2008). The D1R gene is
expressed early (Lee-Chen, et al., 1988) and has been shown to have multiple roles in the
VACV replication cycle. It functions not only as a capping enzyme, but also has roles in
early gene transcription termination and in intermediate gene transcription initiation
(Harris, et al., 1993, Hassett, et al., 1997, Shatzer, et al., 2008). After careful
consideration, the D1R gene was chosen as the ideal essential gene because it was shown
to be required for VACV replication and it is expressed under an early promoter (its
repression should be able to stop replication of VACV at an early stage of the virus life
cycle).
To utilize the D1R gene to generate an inducible recombinant VACV that
replicates only in the presence of tetracyclines, tetO sequences were incorporated into the
promoter for the D1R gene and by inserting the tetR gene (under a constitutive promoter)
into the VACV genome. The resulting recombinant VACV (viD1R) was expected to be
able to replicate only in the presence of tetracyclines.
Two recombinant VACVs were be designed: 1) viD1R (for VACV Inducible
D1R) expressing TetR constitutively and having the D1R gene under the control of a tetresponsive early synthetic promoter (PiSE). The replication of this virus was expected to
occur only in the presence of tetracyclines. 2) viD1Rc (for VACV Inducible D1R
control) also expressing TetR constitutively but having the D1R gene under the control of
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its natural promoter (PD1R). This virus was expected to replicate both in the presence and
absence of tetracyclines.
The strategy aims to control the replication of VACV by inducing the essential
gene through the addition of tetracyclines (e.g., doxycycline). This control over viral
replication will increase the safety of VACV as a vaccine vector. If adverse events arise
after vaccination with the recombinant VACV, the removal of doxycycline will stop or
greatly attenuate the replication of the virus, giving the innate and adaptive immune
systems the opportunity to clear the virus, stopping the adverse event.

2.2. MATERIALS AND METHODS

2.2.a. Research Design:
An inducible recombinant VACV was designed by incorporating tetO sequences into
the promoter for the VACV D1R essential gene and inserting the tetR gene (under a
constitutive promoter) into the D1R-H7R intergenic region of the VACV genome. The
resulting recombinant VACV (viD1R) is expected to be able to replicate only in the
presence of tetracyclines.

Recombinant viruses designed:
1. viD1R (for VACV Inducible D1R) expressing TetR constitutively and
having the D1R gene under the control of a tet-responsive early synthetic
promoter (PiSE) -- replication of this recombinant should only occur in the
presence of tetracyclines.
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2. viD1Rc (for VACV Inducible D1R control) also expressing TetR
constitutively but having the D1R gene under the control of its natural
promoter (PD1R) -- replication of this recombinant should occur both in the
presence and absence of tetracyclines.

2.2.b. Early Tet-Responsive Promoter Design for viD1R:
Typical poxvirus promoters are about 30 bp in length with a core, spacer, and
initiator regions (Moss, 2007). Early VACV promoters have a fairly conserved core
region followed by an 11-16 bp spacer and a single purine initiator sequence (Broyles,
2003, Chakrabarti, et al., 1997, Davison and Moss, 1989, Moss, 2007). Extensive
analysis of the early core sequences performed in the Verardi Laboratory suggested that
the sequence, AAAAATAGAAACCATA, would serve as an optimal early core region
(J. Sopronyi et al., unpublished data). To generate an early tet-responsive promoter for
the D1R gene, the 19-bp tet operator sequence O2 (TCCCTATCAGTGATAGAGA) was
inserted between this designed core region and the translational start site of the D1R gene
to originate the synthetic early promoter PiSE (AAAAATAGAAACCATATCCCTATCAGTGATAGAGA). This new synthetic promoter would be expected to have the lowest
levels of expression under repressible conditions, since the putative purine initiator
sequences (underlined) are part of the operator sequence (in bold) (Table 2-1).

2.2.c. Natural D1R Promoter Sequence for viD1Rc:
To generate an appropriate control virus expressing D1R constitutively, the
intergenic sequence between the D1R and the upstream H7R gene coding sequences, plus
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the last 9 bp from the H7R gene coding sequence, were used to design the natural D1R
promoter sequence (PD1R, GCTTGTTAATAAGTAAATGAAAAAAAACTAGTCGTTTATAATAAAACACGAT). H7R, the gene upstream from D1R, has a role in the
formation of crescent membrane precursors and immature virions (Satheshkumar, et al.,
2009). Since the D1R promoter has not been mapped, the 9 bp from the end of the H7R
gene (in bold) were incorporated to ensure that the full natural D1R promoter is present
(Table 2-1). In particular, any potential G nucleotides (required by early promoters
around position -21) were included in the sequence (Broyles, 2003, Chakrabarti, et al.,
1997, Davison and Moss, 1989, Moss, 2007).

Table 2-1: Recombinant Vaccinia Viruses and their Respective D1R Promoter
Sequences.
Recombinant

Inducible

Vaccinia

Promoter

Virus

Name

viD1R

PiSE

AAAAATAGAAACCATATCCCTATCAGTGATAGAGA

viD1Rc

PD1R

GCTTGTTAATAAGTAAATGAAAAAAAACTAGTCGTTTAT-

Promoter Sequencea

AATAAAACACGAT
a

In the PiSE promoter the tetO2 sequence is in bold and underlined are potential early

initiators of transcription. In the PD1R promoter the last 9 bp of the upstream H7R gene
are in bold.

2.2.d. Construction of Transfer Vectors for viD1R and viD1Rc:
A series of cloning steps was used to build the transfer vectors to generate the
recombinant VACVs, based on existing plasmids and designed synthetic DNA
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sequences. The final transfer vectors contain: (1) the selectable E. coli xanthine-guanine
phosphoribosyl transferase (gpt) gene and the screening marker β-glucuronidase (gusA)
gene, as a fusion gene (gpt-gus) under control of the synthetic early/late promoter Psel
(Hammond, et al., 1997); (2) a second screening marker, the DsRed-Express gene
(DsRed) encoding a red fluorescent protein under control of the natural late P11 promoter;
(3) the repressor gene tetR under the synthetic early/late promoter PE/L (Chakrabarti, et
al., 1997); and (4) either the PiSE or PD1R promoter to direct the expression of the D1R
gene.
All of these elements were placed between the left border (LB) (the last 524 bp of
the H7R gene, upstream of D1R) and right border (RB) (the first 600 bp of the D1R
gene), which serve as recombination sequences for homologous recombination. Briefly,
the EcoRI-BglII fragment (containing gtp-gus and DsRed genes) from pSMART10
(Weber, et al., 2007) was cloned into the EcoRI-BclI site of pCH001 (a synthetic plasmid
containing the left and right recombination sequences for assembly of the final transfer
vectors obtained from DNA2.0 (Menlo Park, CA), originating pCH003. Next the SphIXmaI fragment of pSMART10 (containing tetR) was cloned into the same sites of
plasmid pCH003, resulting in the final transfer vector (pCH004), which was used to
generate viD1R (Figure 2-1). To generate the final transfer vector for viD1Rc, the SphIXhoI fragment of plasmid pCH004 (containing PiSE and the Right Border) was replaced
with the SphI-XhoI fragment of the synthetic plasmid pCH002 (containing PD1R and the
Right Border, DNA2.0), generating plasmid pCH005 (Figure 2-1).
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Figure 2-1.. Construction of F
Final Transfer Vectors
ectors pCH004 and pCH005. The
cloning steps used to generate the final transfer vectors are depicted
depicted. Both vectors
express the gpt-gus,, DsRed, and tetR genes under constitutive promoters. The transfer
vector pCH004 was designed to express the D1R gene under the synthetic inducible early
PiSE promoter, while pCH005 expresses the D1R gene under its natural early promoter
(PD1R). All of these genetic elements for both plasmids are flanked by the Left Border
(H7R LB) and Right Border (D1R RB) sequences, which direct homologous
recombination with the VACV genome to generate viD1R and vi
viD1Rc.

2.2.e. Generation of Recombinant Viruses:
Homologous recombination was used to precisely insert th
thee genetic elements
between the left and right bborders
orders of each of the final transfer vectors into the intergenic
region between the essential and upstream genes, placing the inducible promoter in front
of the essential gene. This step replaced the natural D1R
D1R-H7R intergenic region (43 bp)
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with the desired genetic elements (for viD1R 3865 bp were inserted; for viD1Rc 3871 bp
were inserted). The recombinant VACVs were generated by standard homologous
recombination via transfection of the transfer vectors pCH004 and pCH005 into BS-C-1
cell monolayers infected 2 h earlier at 0.05 PFU per cell with VACV strain Western
Reserve (WR) clone 9.2.4.8 (obtained from T. Yilma, University of California Davis).
Recombinant gpt-positive VACVs were plaque purified on BS-C-1 cells from
transfection lysates using gpt selection medium (25 µg/ml mycophenolic acid, 250 µg/ml
xanthine, and 15 µg/ml hypoxanthine) (Legrand, et al., 2004). All recombinants were
plaque-purified in the presence of inducer (1 µg/ml doxycyline). Expression of DsRed
was detected via fluorescence microscopy (Carl Zeiss Axio Observer D1) to ensure that
the recombinant viruses were free of parental virus.

2.3. RESULTS
During plaque purification of the recombinant viruses it was observed that many
of the recombinant plaques that grew in gpt selective media were not expressing DsRed,
but were expressing the gus gene indicating that the recombinants (both viD1R and
viD1Rc) do not contain all of the inserted genetic elements (Figure 2-2). It was also
observed that doxycycline had no effect on the replication of viD1R, the virus replicated
both in the presence and absence of doxycycline.
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Figure 2-2. viD1R Grown in Selective Media Produces
uces Fluorescent and NonN
Fluorescent Plaques. BS
BS-C-1 cells pre-incubated with gpt-selective
selective media were infected
with viD1R and plaques were observed at approximatel
approximately 48 h post infection. Both
DsRed
sRed fluorescent plaques and non
non-fluorescent
fluorescent plaques (shown inside the white circles)
were observed.

2.4. DISCUSSION
The promoters used to express the gpt-gus, DsRed, and TetR genes are made up of
very similar sequences that could promote recombination once inserted into the VACV
genome. The variety of gpt positive recombinants that were observed could be the result
of recombination
ecombination between the promoters. In particular, recombination
ecombination between the P11
promoter for DsRed and the PSEL promoter for gpt-gus would
ld cause the recombinants to
lose the DsRed gene while maintaining TetR and gpt-gus expression. Recombination
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between the PE/L promoter for gpt-gus and the PE/L promoter for TetR would
uld cause the
recombinants to lose
ose both the DsRed and TetR genes while retaining the gpt-gus
gpt
gene. If
recombination occurred between the PE/L and P11 the TetR gene would be removed from
the virus without altering the gpt-gus or DsRed genes. This recombination could explain
why the viD1R virus was not responsive to doxycycline (Figure 2-3).. Due to the
recombination events occurring in the virus, the transfer vectors were re-designed to
decrease the likelihood of recombination.

Figure 2-3. Possible Recombination
ecombination among Promoters within viD1R and viD1Rc.
viD1Rc
Depicted are possible recombination events that could occur within the viD1R and
viD1Rc recombinants.
ombinants. A) R
Recombination between P11 and PE/L would result in the
removal of the tetR gene while maintaining DsRed. B) Recombination
ecombination between P11 and
PSEL results in the loss of DsRed while maintaining tetR. C) Recombination
ecombination between PSEL
and PE/L results in the loss of both DsRed and tetR expression.
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CHAPTER 3: IMPROVEMENT OF TRANSFER VECTORS
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3.1. INTRODUCTION
Due to the instability in the viD1R and viD1Rc viruses, the transfer vectors
needed to be re-designed
designed to decrease the likelihood of recombin
recombination events. Transfer
vectors for viD1R and viD1Rc were re
re-designed
designed to minimize the number of promoters
utilized, thus preventing recombination from occurring within the inserted sequence
(Figure 3-1).. Placing similar/identical sequences (e.g, promoters) in very close proximity
to each other (e.g, back-to
to-back)
back) prevents recombination from occurring between the
sequences. By reducing the number of promoters used to two, the two promoters may be
identical and placed back
back-to-back to prevent recombination. If this
his setup is utilized,
utilized the
only promoter in a location within the transfer vector that could undergo recombination is
the synthetic early promoter (PiSE). If recombination occurs with this promoter,
promoter the
expression of the newly designed gpt-EGFP (enhanced green fluorescent protein) fusion
protein would be lost, causing these viruses not to grow in gpt
gpt-selective
selective media.

design of Transfer V
Vectors. An overview of the design of the final
Figure 3-1. Re-design
transfer vectors is shown. The original transfer vector design is depicted in A and the new
design is shown in B. The new design (B) minimizes the us
use of synthetic VACV
promoters and arranges them in a way to minimiz
minimize recombination.
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3.2. MATERIALS AND METHODS

3.2.a. Re-design of Transfer Vectors for viD1R and viD1Rc:
A new gpt-EGFP fusion gene was generated. A synthetic plasmid containing the
EGFP sequence with an NcoI site at the 5’ end and an AatII-EcoRI site at the 3’ end
(pCH035) was used to generate the gpt-EGFP fusion gene. The synthetic EGFP gene
was cloned into the pSMART10 plasmid (replacing the GUS gene) to generate pCH030
containing the gpt-EGFP fusion gene. The fusion gene was sequenced to confirm the
sequence of gpt-EGFP.
A series of cloning steps was then used to build the transfer vectors to generate
the recombinant VACVs (viD1R2 and viD1Rc2), based on existing plasmids and designed
synthetic DNA sequences. The final transfer vectors contain: (1) the selectable E. coli
xanthine-guanine phosphoribosyl transferase (gpt) gene and the screening marker EGFP
gene, as a fusion gene (gpt-EGFP) under control of the synthetic early/late promoter PE/L;
(2) the repressor gene tetR under PE/L promoter (Chakrabarti, et al., 1997); and (4) either
the PiSE or PD1R promoter to direct the expression of the D1R gene.
All of these elements were placed between the left border (the last 524 bp of the
H7R gene, upstream of D1R) and right border (the first 600 bp of the D1R gene), which
serve as recombination sequences for homologous recombination. Briefly, the EcoRISphI fragment (containing back-to-back PE/L promoters) from pCH029 (from DNA2.0)
was cloned into the EcoRI-SphI site of pCH001 (a synthetic plasmid containing the left
and right recombination sequences for assembly of the final transfer vectors obtained

30

from DNA2.0), originating pCH031. Next the XmaI-NheI fragment of pCH004
(containing tetR) was cloned into the same sites of plasmid pCH031, resulting in
pCH032. Finally the SacI/AatII fragment from pCH030 (containing the gpt-EGFP gene)
was inserted into the same site of pCH032 generating the final transfer vector pCH033,
which was used to generate viD1R2 (Figure 3-2). To generate the final transfer vector for
viD1Rc2, the SphI-XhoI fragment of plasmid pCH0033 (containing PiSE and the Right
Border) was replaced with the SphI-XhoI fragment of the synthetic plasmid pCH002
(containing PD1R and the Right Border, DNA2.0), generating final transfer vector
pCH034 (Figure 3-2).
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Figure 3-2. Construction of Final Transfer Vectors pCH033 and pCH034. The
cloning steps used to generate the final transfer vectors are depicted. Both vectors
express the gpt-EGFP,, and tetR genes under constitutive promoters. The transfer
trans vector
pCH033
033 was designed to express the D1R gene under the synthetic
hetic inducible early PiSE
promoter, while pCH005 expresses the D1R gene under its natural early promoter (PD1R).
All of these genetic elements for both plasmids are flanked by the left border (H7R LB)
and right border
order (D1R RB) sequences, which direct hom
homologous
ologous recombination with the
VACV genome to generate vi
viD1R2 and viD1Rc2.
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3.2.b. Generation of Recombinant Viruses:
Recombinant viruses were generated using the method previously described in
Chapter 2, section 2.2.e.

3.3. RESULTS
Upon plaque purification, no recombination was observed in the recombinant
VACVs, since all genetic screening/selective genetic elements appeared to be expressed.
The recombinant viruses were able to grow in MPA selective media and to express EGFP
(indicating that the viruses were gpt+ and EGFP+), and contained the tetR gene as
determined by PCR (data not shown). The current genetic setup appears to prevent
recombination from occurring among the transfer vector elements. Upon testing with
doxycycline there was no observable effect on the replication of either viD1R2 or
viD1Rc2. Plaques of similar size were formed both in the presence and in the absence of
doxycycline, indicating that viral replication is not inducible (Figure 3-3).
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Figure 3-3. Effect of Doxy
Doxycycline on the Replication of viD1R2 and viD1Rc2. BS-C1 cells were infected with virus and allowed to grown for 48 h in either the presence of 1
µg/ml doxycycline or in the absence of doxycycline.

3.4. DISCUSSION
Minimizing the number of promoters used in the transfer vectors successfully
prevented recombination from occurring among the inserted genetic elements. However,
the recombinant viD1R2 was not inducible; the virus was able to grow in the presence
and absence of doxycycline
doxycycline. There are several possible reasons for why the tet operon
elements were unable too control the replication of this recombinant VACV. First, as D1R
is expressed early in infection there may not be enough TetR packaged into the virion to
prevent this early
rly transcription effic
efficiently.
iently. Although early promoters are weak, the D1R
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gene product (small subunit of the capping enzyme) is an enzyme and may not be
required in high amounts, thus a low level of early transcription may produce a sufficient
amount for viral replication. Secondly, as the structure of early promoters is not well
understood, the operator sequence may not have been inserted in an ideal location
causing the binding of TetR to be insufficient to prevent transcription of D1R.
To date, no early gene has ever been successfully controlled by an operon system
while maintaining its early expression. Limited success has been achieved by changing
the stage at which the early gene of interest is transcribed, as was done with the L2R
gene. The L2R gene is expressed early in infection, but in an attempt to study its function
using the lac operon, the promoter of the gene was changed to a T7 RNA polymerase
promoter. Utilizing a genetic arrangement, in which the T7 RNA polymerase is under the
control of a late promoter containing a lacO sequence, the transcription of L2R was
successfully regulated by IPTG. Although gene expression was successfully regulated, a
delay in virus replication of several hours was observed possibly due to the change in the
time of expression of L2R (Maruri-Avidal, et al., 2011).
Due to the inherent difficulties in regulating early transcription using operon
systems as observed in this system and by others as well, late VACV genes may be better
candidates for the inducible control of VACV replication.
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CHAPTER 4: USE OF VACCINIA VIRUS LATE GENES TO
CONTROL VIRAL REPLICATION
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4.1. INTRODUCTION
Controlling early gene expression through the use of operon systems has proven
to be very challenging; controlling late gene expression may be a better alternative to
generate inducible VACV recombinants. Several inducible VACVs were designed by
placing late genes essential for VACV replication under the control of tet operon
elements, allowing viral replication to occur only in the presence of tetracyclines. These
inducible recombinant VACVs were designed by incorporating tetO sequences into the
promoters for selected essential late genes (A3L, A6L, A7L, D6R, E8R, and F17R) and
inserting the tetR gene (under a constitutive promoter) into the VACV genome. The
resulting recombinant VACVs were expected to only be able to replicate in the presence
of tetracyclines.
The late essential genes were selected based on their presumed function in the
virus life cycle (e.g., RNA and DNA polymerases, transcription factors, etc.) and on
published experimental work. A total of 27 late essential candidate genes were initially
identified. The promoters of each gene were then investigated to determine if a
characteristic late transcription initiator (TAAAT) was present and the positions of these
genes in the VACV genome and their upstream intergenic regions (the region between
the start site of the essential gene candidate and the upstream gene) were carefully
inspected to determine if it would be possible to insert the tet operon elements without
disrupting transcription of the surrounding genes. For example, the RNA polymerase 132
kDa subunit (A24R) is not an ideal essential gene candidate because its promoter is
located within the upstream gene (A23R). Inserting tet operon elements into this
intergenic region would cause the transcription of the both the essential gene and the
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upstream gene to be affected. Similarly, the E10R gene is not an ideal candidate because
its promoter is back-to-back with the early promoter for the DNA polymerase gene
(E9L). As the exact sequence of the early promoter for E9L could not be accurately
determined and transcription of E9L would likely be disrupted by inserting the tet operon
elements into this intergenic region, the E10R gene was not considered an ideal
candidate. This analysis further narrowed the list of candidate genes; all remaining genes
with appropriate intergenic regions were then further researched to determine if they
would be able to control VACV replication. Based on this criteria the following late
essential genes were chosen: A3L (precursor of core protein 4b), A6L (involved in the
formation of mature virions), A7L (large subunit of the early transcription factor), D6R
(small subunit of the early transcription factor), E8R (membrane protein), and F17R
(virion core protein).

4.1.a. A3L Gene:
The A3L gene encodes the 72.5 kDa precursor to virion core protein 4b.
Precursor 4b is proteolytically processed by the I7L gene product into 4b, a 60 kDa core
protein. Core protein 4b accounts for 11% of the virion mass and has been localized to
the surface of virion cores (Moss and Rosenblum, 1973, Sarov and Joklik, 1972, Wilton,
et al., 1995). Temperature sensitive mutants that map to the A3L gene were used to
investigate the role of A3 in virion morphogenesis. These mutants had normal patterns of
gene expression and DNA replication, but were defective in the transition from immature
virions containing nucleoids (IVN) to intracellular mature virus (IMV) (Kato, et al.,
2004). Infections at the nonpermissive temperature formed normal IV (immature virions)
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and IVN, but no normal IMVs were produced. The particles that were produced were
abnormal in shape. The infectivity of these misshapen virions was reduced 30-100 fold
and showed transcription levels as low as 2% of wild type levels (Kato, et al., 2004).
Repression of the I7L gene product, which is responsible for cleaving the precursors of
core protein 4b as well as core proteins 4a and 25k, also causes a defect in virion
morphogenesis very similar to the A3L temperature sensitive mutants, further suggesting
that core protein 4b is essential to VACV (Ansarah-Sobrinho and Moss, 2004, Byrd and
Hruby, 2005, Kane and Shuman, 1993). An inducible A3L VACV mutant has not yet
been generated.

4.1.b. A6L Gene:
VACV gene A6L is one of 91 open reading frames (ORFs) conserved among all
chordopoxviruses (Upton, et al., 2003). A6 has been shown to be a minor virion
component in VACV via mass spectrometry (Chung, et al., 2006). The A6 homolog of
myxoma virus has also been identified as part of the virion core (Zachertowska, et al.,
2006). Temperature sensitive mutants and a recombinant VACV encoding A6L with an
epitope tag have been used to characterize the function of the A6L gene in the VACV
lifecycle. The A6L gene product is expressed late in infection, tightly packaged into the
virion core and appears to be essential in virion morphogenesis (Meng, et al., 2007). At
the non-permissive temperature, ts-mutants were unable to produce infectious progeny
and could not process the precursors of major virion proteins 4a and 4b (Meng, et al.,
2007). At the non-permissive temperature, virion morphogenesis of the ts-mutants was
blocked at the IV stage prior to IVN. Several proteins co-precipitate with A6 leading to
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speculation that A6 may help with assembly of the virion core through its interaction with
other viral proteins. An inducible recombinant for the A6L gene has not yet been
successfully constructed. Lac operon inducible recombinants for the A6L gene have been
attempted, but have not been successfully generated (Meng, et al., 2007).

4.1.c. A7L and D6R Genes:
The VACV early transcription factor (VETF) is composed of two subunits (a
small 70 kDa subunit and a large 82 kDa subunit). The D6R gene encodes the small
subunit and the large subunit is encoded by A7L. The VACV A7L gene is referred to as
A8L in some literature; currently the A8 ORF is considered to be A8R and to encode a
subunit of the intermediate transcription factor (Sanz and Moss, 1999). The VETF
subunits are produced late in infection and packaged into the virus to be used in the next
round of replication. VETF provides early promoter specificity to the RNA polymerase,
by binding early promoters and recruiting the RNA polymerase for transcription of early
genes (Baldick, et al., 1994, Li and Broyles, 1993b). The H4L gene product (RAP94) is
also required for early gene transcription and is believed to have a role in docking the
RNA polymerase to the VETF (Ahn, et al., 1994, Broyles, 2003). A7, the large subunit,
interacts with the core region of the early promoter while D6, the small subunit, interacts
with the promoter’s downstream region (Cassetti and Moss, 1996). The small subunit of
the VETF also contains the DNA-dependent ATPase activity of the transcription factor
(Li and Broyles, 1993a).
An inducible A7L VACV mutant was created using the lac operon system. The
T7 RNA polymerase gene, under the VACV late P11 promoter containing a lac operator,
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was inserted into the VACV genome and the A7L gene was placed under the control of a
bacteriophage T7 promoter. This inducible system used IPTG to regulate the production
of the T7 RNA polymerase and thus the transcription of the A7L gene. The replication of
this mutant was shown to be dependent on inducer and the repression of A7 interfered
with virion morphogenesis. In the absence of inducer, one-step growth curves showed
little or no increase in viral titer compared to a 2-log increase in the presence of inducer.
The repression of A7 produced immature and dense intermediate particles that did not
have the characteristic brick structure and very few mature particles were produced.
Only 5.6% of all particles formed were mature virions compared to 33.4% in the presence
of inducer (Hu, et al., 1998).
An inducible D6R mutant was also generated using the T7lacO system. The D6R
gene was placed under the control of a T7 promoter and the inserted T7 RNA polymerase
gene was regulated by the VACV late P11 promoter with a lac operator, causing the D6R
gene to be inducible by IPTG. Plaque formation of this mutant was dependent on the
presence of inducer. Similar to the repression of A7, the repression of D6 also interfered
with morphogenesis of the virus. In the absence of inducer, immature virions were found
next to large granular masses and were round rather than brick shaped, and mature
virions were not frequently observed (Hu, et al., 1996).
The disruption of virion morphogenesis caused by the repression of the VETF
subunits may indicate a direct role for the VETF in virion morphogenesis or VETF may
be required for the transcription of a unique set of late genes (Hu, et al., 1996, Hu, et al.,
1998). The possibility of the VETF being required for transcription late in infection

41

supports the transcriptional reactivation of certain early promoters at late times (Garces,
et al., 1993). Neither prospective role for VETF has yet been confirmed.

4.1.d. E8R Gene:
The specific role of the VACV E8R gene has not yet been accurately determined
although several studies have been conducted. E8R was predicted to contain two
transmembrane domains and was first investigated as a potential membrane protein
involved in ER wrapping (Tolonen, et al., 2001). E8R was shown to localize to DNA
replication sites and to be concentrated in the ER surrounding the replication site. Based
on these findings E8R was suggested to be an ER-resident membrane protein that may
bind newly synthesized VACV DNA and aid in ER wrapping (Tolonen, et al., 2001).
Due to the suggested role of aiding in ER wrapping, the E8R gene was further
investigated leading to conflicting reports on the characteristics of E8R and its role in the
VACV life cycle.
Doligo et al. further characterized the E8R gene product as being made early in
infection and as being associated with the ER membrane as early as 1 hour postinfection. E8 was also shown to associate with the membranes of immature virions (IV),
intracellular mature virus (IMV), and with viral cores. E8 is phosphorylated in vitro by
F10 kinase, a process that was shown to reduce the binding of DNA to E8. Based on
this information it was speculated that E8R might mediate the binding of DNA to ER
membranes leading to the enclosure of the replication site by ER membranes (Doglio, et
al., 2002).
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The role of E8R was also investigated using ts-mutants; the results from these
experiments are inconsistent with the characterization by Doligo et al. Kato et al. showed
E8R to be expressed late in infection, contrary to previous reports. Upon investigation of
the promoter and gene, sequences consistent with a late gene promoter were found. The
coding sequence was also shown to contain two early transcription termination sequences
further supporting the conclusion that E8 is a late protein (Doglio, et al., 2002, Kato, et
al., 2007).
Ts-mutants in the E8R gene synthesized DNA and proteins at the same level for
both permissive and non permissive temperatures, indicating that an absence or decrease
of E8 protein did not affect the DNA factories, as would have been expected if E8 had a
role in them. Ts-mutants and wild type viruses produced similar amounts of particles per
cell at permissive and non-permissive temperatures, but the infectivity of the ts-mutant
particles at the non-permissive temperature was greatly decreased. The infectivity of tsmutants grown at non-permissive temperatures was reduced 35 fold compared to the
same virus grown at permissive temperatures (Kato, et al., 2007).
Virions grown at non-permissive temperatures were able to enter cells; however,
the virions were defective in early viral transcription, producing only 10% the amount of
RNA compared to wild type. Although the virions were defective in early transcription,
their extracts were able to synthesize RNA transcripts similar to wild type indicating that
the mutant virions contain all the necessary factors for transcription. The E8R mutants
resemble L3L ts-mutants in that both form virus particles indistinguishable from wild
type, but that are deficient in early transcription within the core. Contrary to the
conclusions of Dolgio et al. and Tolonen et al., Kato et al. concluded that E8 appears to
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have a role in the virion core structure which impacts core transcription (Kato, et al.,
2007). No definitive role for E8 has been established and an inducible E8R VACV
mutant has not yet been generated.

4.1.e. F17R Gene:
F17R, also referred to as F18 or p11, is one of the most abundant core proteins,
accounting for 11% of the virion mass (Sarov and Joklik, 1972). F17 binds strongly to
DNA and has been characterized as a DNA-binding protein (Kao and Bauer, 1987, Kao,
et al., 1981). In 1991, an inducible F17R recombinant was generated using the lac
operon. LacI was constitutively expressed and the lac operator inserted between the
gene’s translational start site and its promoter. This recombinant was unable to replicate
in the absence of inducer (IPTG) (Zhang and Moss, 1991a). The inducible F17R mutant
was the first conditional-lethal VACV mutant generated using any operon system. In the
absence of inducer, cleavage of the major virion protein precursors (p4a and p4b) was
inhibited and morphogenesis was blocked at an intermediate stage (Zhang and Moss,
1991b). Further investigation determined that in the absence of F17 no typical mature
virions are formed, and immature virions with unusual internal membranes and aberrant
noninfectious mature virions are produced (Wickramasekera and Traktman, 2010).
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4.2. MATERIALS AND METHODS

4.2.a. Research Design:
Inducible recombinant VACVs were designed by incorporating tetO sequences
into the promoters for the selected essential late genes (A3L, A6L, A7L, D6R, E8R, and
F17R) and inserting the tetR gene (under a constitutive promoter) into the VACV
genome. The resulting recombinant VACVs were expected to only be able to replicate in
the presence of tetracyclines.

Six recombinant VACVs have been designed:
1. viA3L (for VACV Inducible A3L) expressing TetR constitutively and having the
A3L gene under the control of the tet-responsive A3L promoter (PiA3L).
2. viA6L (for VACV Inducible A6L) expressing TetR constitutively and having the
A6L gene under the control of the tet-responsive P11 (F17R) promoter (Pi11).
3. viA7L (for VACV Inducible A7L) expressing TetR constitutively and having the
A7L gene under the control of the tet-responsive P11 (F17R) promoter (Pi11).
4. viD6R (for VACV Inducible D6R) expressing TetR constitutively and having the
D6R gene under the control of the tet-responsive D6R promoter (PiD6R).
5. viE8R (for VACV Inducible E8R) expressing TetR constitutively and having the
E8R gene under the control of the tet-responsive E8R promoter (PiE8R).
6. viF17R (for VACV Inducible F17R) expressing TetR constitutively and having
the F17R gene under the control of the tet-responsive F17R promoter (Pi11).
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4.2.b. Tet-Responsive Late Promoter Design:
Late VACV promoter sequences are less conserved than early promoters, but
have a very distinct initiator sequence. Late VACV promoters commonly consist of a 20
bp long T-run, a 6 bp spacer region, and a highly conserved TAAAT initiator sequence
(Davison and Moss, 1989). To make a promoter tet-responsive the operator sequence is
added downstream of the initiator. The P11 promoter of VACV has previously been used
as a lac-responsive and tet-responsive promoter (Fuerst, et al., 1989, Weber, et al., 2007)
To make the P11 promoter tet-responsive, the tetO2 sequence (TCCCTATCAGTGATAGAGA) was inserted downstream of the initiator to generate Pi11 (Weber, et al., 2007). The
synthetic PE/L promoter has also successfully been made tet-responsive by inserting the
tetO2 sequence after the initiator. To transform the promoters of the chosen essential late
genes into tet-responsive promoters, their promoters and intergenic regions were studied.
The A3L intergenic region is 52 bp and is expected to contain only the late
promoter for the A3L gene. The entire intergenic sequence was used for the A3L
promoter to ensure the entire promoter would be used in its natural state. The tet O2
sequence was then inserted after the putative late initiator sequence (TAAATA)
generating PiA3L (Figure 4-1 and Table 4-1).
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Figure 4-1. A3L Region of the Vaccinia Virus G
Genome. The A3L gene and
surrounding genes are shown, with bp sizes of the genes (below) and intergenic regions
(above).

The A6L intergenic region is only 23 bp, and since it is shorter than the typical
poxvirus promoter length, it is likely that the start of the A6L promoter is located within
the upstream gene. When the intergenic region was carefully inspected, the sequence
contained several possible late initiator sequences and the sta
start
rt of the promoter could not
be identified with confidence
confidence; therefore the intergenic region containing the natural A6L
promoter was removed and the Pi11 promoter was used to control transcription of the A6L
gene (Figure 4-2 and Table 44-1).

Figure 4-2. A6L Region
egion of the Vaccinia Virus Genome. The A6L gene and
surrounding genes are shown, with bp sizes of the genes (below) and intergenic regions
(above). A negative size indicates an overlap between genes
genes.
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The A7L intergenic region (53 bp) possibly contains promoters for both the A7L
gene and the A8R gene. It was not possible to accurately identify and separate the
sequences for the two promoters; therefore the Pi11 promoter was used to control the
transcription of the A7L gene (Figure 4-3 and Table 4-1). The intergenic region was kept
in the viral genome to prevent interfering with transcription of the A8R gene and the A7L
natural promoter initiator sequence was changed from TAAAT to TAAGG to prevent
transcription initiator from that site (Table 4-1).

Figure 4-3. A7L Region
egion of the Vaccinia Virus Genome. The A7L gene and
surrounding genes are shown, with bp sizes of the genes (below) and intergenic regions
(above).

D6R has an intergenic region of 40 bp that is expected to contain only the late
promoter for the D6R gene. The entire D6R intergenic sequence was used as the natural
promoter of D6R and the tet O2 sequence was inserted after the putative late initiator
sequence (TAAATA) to generate the tet-responsive D6R promoter PiD6R (Figure 4-4 and
Table 4-1).
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Figure 4-4. D6R Region
egion of the Vaccinia Virus Genome. The D6R gene and
surrounding genes are shown, with bp sizes of the genes (below) and intergenic regions
(above).

The entire intergenic sequence of E8R (124 bp) with the tetO2 sequence inserted
after the putative late initiator (TAAATA
(TAAATA) was used to generate PiE8R (Figure 4-5 and
Table 4-1). The entire intergenic region, which only contains the promoter for E8R, was
used to ensure that the entire natural promoter for the gene was included..

egion of the Vaccinia Virus Genome. The E8R gene and
Figure 4-5. E8R Region
surrounding genes are shown, with bp sizes of the genes (below) and intergenic regions
(above).

The natural promoter for the F17R gene is the P11 promoter. The intergenic
region of the F17R gene is 62 bp and contains both the promoter for the F17R gene and
for the F16L gene (Figure 4-6). The previously designed Pi11 promoter was used as the
tet-responsive F17R promoter and 2 bp of the F17R promoter were repeated and included
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as part of the F16L promoter to ensure the entire F16R promoter remains in its natural
state.

Figure 4-6. F17R Region
egion of the Vaccinia Virus Genome. The F17R gene and
surrounding genes are shown, with bp sizes of the genes (below) and intergenic regions
(above). A negative size indicates an overlap between genes
genes.

Table 4-1: Essential Gene Tet
Tet-Responsive
Responsive Promoter Sequences.
Essential

Inducible

VACV

Promoter

Gene

Name

A3L

PiA3L

Promoter Sequencea

ATAAGATTGGATATTAAAATCACGCTTTCGAGTAAAAAC
TACGAATATAAATATCCCTATCAGTGATAGAGA
TCCCTATCAGTGATAGAGA

A6L

Pi11

ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTATAAAT
ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTA
ATCCCTATCAGTGATAGAGA

A7L

Pi11

ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTATAAAT
ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTA
ATCCCTATCAGTGATAGAGA

D6R

PiD6R

ATATATGCTCATATATTTATAGAAGATATCACATATCTAA
ATATATGCTCATATATTTATAGAAGATATCACATATC
ATATCCCTATCAGTGATAGAGA

E8R

PiE8R

GTATAATCCCATTCTAATACTTTAACCTGATGTATTAGCA
TCTTATTAGAATATTAACCTAACTAAAAGACATAACATA
AAAACTCATTACATAGTTGATAAAAAGCGGTAGGATATA
AAAACTCATTACATAGTTGATAAAAAGCGGTAGGATA
AATATCCCTATCAGTGATAGAGA

F17R

Pi11
(PiF17R)

a

ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTATAAAT
ATATAGTAGAATTTCATTTTGTTTTTTTCTATGCTA
ATCCCTATCAGTGATAGAGA

Initiator sequences are in bold; tetO2 sequences are underlined.
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4.2.c. Construction of Transfer Vectors for viA3L, viA6L, viA7L, viD6R, viE8R, and
viF17R:
A series of cloning steps was used to build the transfer vectors based on existing
plasmids and designed synthetic DNA sequences. The final transfer vectors contain: (1)
the selectable E. coli xanthine-guanine phosphoribosyl transferase (gpt) gene and the
screening marker EGFP gene, as a fusion gene (gpt-EGFP) under control of the synthetic
early/late promoter PE/L; (2) the repressor gene tetR under the synthetic early/late PE/L
promoter (Chakrabarti, et al., 1997); (3) a tet-responsive promoter to direct the expression
of the essential gene; and (4) a left border sequence (600 bp of the gene upstream of the
essential gene) and a light border sequence (the first 600 bp of the essential gene or
intergenic region) to serve as recombination sequences for homologous recombination.
The SphI-XmaI fragment (containing the gpt-EGPF gene, tetR gene, and a spacer
region) from pCH033 was cloned into the SphI-XmaI site of pCH051 (A3L), pCH052
(A6L), pCH053 (A7L), pCH054 (D6R), pCH055 (E8R), and pCH056 (F17L) (synthetic
plasmids containing the essential gene tet-responsive promoter, and respective left and
right recombination sequences (obtained from DNA2.0, Menlo Park, CA). This step
generated the final transfer vectors: pCH057 (viA3L), pCH058 (viA6L), pCH059
(viA7L), pCH060 (viD6R), pCH061 (viE8R), and pCH062 (viF17R) (Figure 4-7).
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Figure 4-7. Construction of Final Transfer Vectors pCH057, pCH058, pCH059,
pCH060, pCH061, and pCH062
pCH062. The cloning step used to generate the final transfer
vectors are depicted. All final transfer vectors express the gpt-EGFP and tetR genes
under constitutive
titutive promoters
promoters. Each transfer vector was designed to express their
the essential
gene under a tet-responsive
responsive late promoter. All of the genetic elements are flanked by left
border (LB) and right border (RB) sequences, which direct homologous recombination
with the VACV genome to generate their respective recombinants.
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4.2.d. Generation of Recombinant Viruses:
Homologous recombination was used to precisely insert the genetic elements
between the Left and Right Borders of each of the final transfer vectors into the
intergenic region between the essential and upstream genes, placing the inducible
promoter in front of the essential gene. The recombinant VACVs were generated by
standard homologous recombination via transfection of the transfer vectors pCH057,
pCH058, pCH059, pCH060, pCH061, or pCH062 into BS-C-1 cell monolayers infected 2
h earlier at 0.05 PFU per cell with VACV strain Western Reserve (WR) clone 9.2.4.8
(obtained from T. Yilma, University of California Davis). Recombinant gpt-positive
VACVs were plaque purified on BS-C-1 cells from transfection lysates using gpt
selection medium (25 µg/ml mycophenolic acid, 250 µg/ml xanthine, and 15 µg/ml
hypoxanthine) (Legrand, et al., 2004). All recombinants were plaque-purified in the
presence of inducer (1 µg/ml doxycycline). Expression of EGFP was detected via
fluorescence microscopy (Carl Zeiss Axio Observer D1) to ensure that the recombinant
viruses were free of parental virus. High-titer stocks were generated by infecting HeLa
S3 cells with the recombinant VACVs at a multiplicity of infection (MOI) of 0.1.
Infected cells were harvested 4 days post-infection by centrifugation at 200 × g for 10
min. Cells were then lysed by freezing and thawing, sonicated, and trypsinized. Finally,
cell lysates were clarified to remove contaminating cell debris by a second round of
sonication and centrifugation at 500 × g for 10 min. The overall genomic structure of
each recombinant VACV was determined by restriction analysis and PCR analysis of
viral DNA, which was purified using a small-scale method employing micrococcal
nuclease (Lai and Chu, 1991).
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4.2.e. The Effect of Doxycycline Concentration on Plaque Size:
The ability of the recombinant viruses to grow in the presence or absence of
inducer (doxycycline) was first investigated by plaque assay. Cell monolayers in six-well
plates were infected at 40 PFU/well, in the presence of 0, 1, 10, 100, or 1000 ng/ml
doxycycline; photographs and measurements of isolated VACV plaques were taken 40 h
postinfection with an inverted microscope. For plaque size measurements, cells were
stained with crystal violet (0.5% in 20% ethanol), and the diameters of plaques were
measured under an inverted microscope (Carl Zeiss Axio Observer D1) with
measurement-capable software (AxioVision). Paired t-tests were used to determine the
significance of doxycycline concentration on the plaque size of the different recombinant
viruses and WR. Unpaired t-tests were used to determine the difference of plaque sizes
between the viruses. All statistical tests were performed with the statistical software
Prism (GraphPad Software Inc, San Diego, CA).

4.2.f. The Effect of Tetracycline, Doxycycline, and Anhydrotetracycline on Plaque
Size:
The ability of the recombinant viruses to grow in the presence of different
tetracyclines was investigated by plaque assay. BS-C-1 cell monolayers in 12-well plates
were infected at 20 PFU/well, in the presence 1 µg/ml of doxycycline, tetracycline, or
anhydrotetracycline. Photographs and measurements of isolated VACV plaques were
taken 40 h postinfection with an inverted microscope. For plaque size measurements,
cells were stained with crystal violet (0.5% in 20% ethanol), and the diameters of plaques
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were measured under an inverted microscope (Carl Zeiss Axio Observer D1) with
measurement-capable software (AxioVision).

4.2.g. Viral Titers with Varying Doxycycline Concentrations:
BS-C-1 cells in 12 well plates were infected at an MOI of 0.01 with WR, viA3L,
viA6L, viA7L, viD6R, viE8R, or viF17R. After 1 h, virus was aspirated and DME/2.5%
FBS with 1000, 100, 10, 1, or 0 ng/ml doxycycline was added. Cells were collected
either 0 h (immediately after the 1 h infection) or at 48 h post-infection. The intracellular
fraction of virus was collected: cells were removed from the wells, centrifuged at 300 x g
for 10 min to pellet the cells, supernatant (containing extracellular virus) was removed
and the cells were resuspended in 500 µl of DMEM. The intracellular fraction was
processed and titered on BS-C-1 cells as previously described (Verardi, et al., 2001), in
the presence of 1 µg/ml of doxycycline.

4.3. RESULTS
4.3.a. Construction of Recombinant Viruses:
Recombinant viruses were successfully constructed and plaque purified. PCR of
viral DNA, purified by small-scale miccrococcal nuclease method, showed all
recombinants to have the genetic elements correctly inserted into the VACV genome
(data not shown).
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4.3.b. Plaque Assays and Plaque Size:
All of the recombinant viruses display unique growth characteristics in response
to doxycycline. Overall, the recombinants viA6L, viA7L, viD6R, and viF17R all
displayed a degree of dependence on doxycycline for viral plaque formation.
Recombinant viA3L and viE8R did not (Figures 4-8 and 4-9).
Recombinants that were dependent on doxycycline for plaque production
produced abortive infections in the absence of doxycycline. Infected cells could be
detected by the expression of EGFP, but no plaques were formed after 48 h post-infection
(Figure 4-10) or even after 1 week post-infection (data not shown).
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Figure 4-8. Viral Plaques in the Presence and Absence of Doxycycline. Wells were
infected with 50 PFU of virus and grown the presence of absence of 1 µg/ml doxyxycline
(Dox), after approximately 48 h cells were stained with crystal violet.
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Figure 4-9. The Effect of Dox
Doxycycline on Plaque Size. Virus was grown in the
presence or absence of 1 µg/ml doxycycline (Dox) for 40 h. After 40 h cells were stained
with crystal violet, a representative image from each treatment is shown above.
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Figure 4-10. Abortive Infection in the Absence of Dox
Doxycycline. A single infected
infe
cell
is shown in the images, the infected cell is detected by the expression of EGFP (seen in
the fluorescence and combined images). The singe infected cell is not detectable in the
brightfield image, as the expression of EGFP is the only indication that virus is present
within the cell.
The recombinant viA3L is not dependent on doxycycline for replication,
replication but at all
doxycycline concentrations tested, viA3L produced slightly smaller plaques than WR.
WR
For example, at 1000 ng/ml, the average plaque radius for viA3L was 563.3 µm,
compared to 645.6 µm for WR. However, this difference was observed even in the
absence of doxycycline, where the average plaque radius for viA3L was 582.4.3 µm,
compared to 653.1 µm for WR, perhaps indicating that viA3L does not express the A3
protein at wild type levels.
viE8R shows some dependence on dox
doxycycline for replication, since plaque size
decreased at 1 ng/ml and 0 ng/ml doxycycline concentration (Figure 4-11
11 and Table 4-2).
4
However, even with no dox
doxycycline present, viE8R was able to replicate and produce
plaques. At 100 ng of dox
doxycycline the plaque
aque radius of WR and viE8R did not differ
significantly.
Recombinants viA6L, viA7L, viD6R, and viF17R all were unable to form plaques
in the absence of doxycyccline (Figure 4-11 and Table 4-2). viA6L formed plaques at
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1000, 100, and 10 ng/ml of doxycycline that were not significantly different in size.
However, at 1 and 0 ng/ml doxycycline no plaques formed, only abortive infections
occurred. At 1000 ng/ml doxycycline the average plaque radius of viA6L (628.2 µm)
was not significantly different from WR (636.8 µm).
viA7L is also dependent on doxycycline for plaque formation; the virus was able
to form plaques at 1000, 100,10, and 1 ng/ml of doxycycline, but only abortive infections
were seen in the absence of doxycycline (Figure 4-11 and Table 4-2). Plaques produced
in the presence of 1000, 100 or 10 ng/ml doxycycline did not differ in size, but plaques
produced at 1 ng/ml doxycycline were significantly smaller at 216.6 µm average radius.
Also, at 1000 ng/ml doxycycline the average plaque size produced by viA7L was
significantly smaller (559.9 µm) than WR (636.8 µm).
viD6R has growth characteristics similar to viA7L, in that it produces plaques at
1000, 100, 10 and 1 ng/ml doxycycline, but does not produce any plaques in the absence
of doxycycline (Figure 4-11 and Table 4-2). The plaque sizes produced by viD6R at 100
ng/ml are significantly larger than at 1000, 10 or 1 ng/ml. A doxycycline concentration
of 1 ng/ml produces significantly smaller plaques (average of 320.1 µm) than at 1000,
100, or 10 ng/ml. The average plaque size of viD6R at 100 ng/ml doxycycline (628.4
µm) is not significantly different than the plaques produced by WR.
The recombinant viF17R responded to doxycycline differently than all other
recombinants. The virus appeared to be attenuated; plaques were only produced at 1000
and 100 ng/ml of doxycycline, and the plaques were much smaller than plaques formed
by any of the other viruses at these concentrations (Figure 4-11 and Table 4-2). The

60

average plaque sizes were 242.7 µm and 281.1 µm respectively. No plaques were
formed at 10, 1 and 0 ng/ml doxycycline.

Table 4-2: Average Plaque Radius (µm) of R
Recombinant and Wild
ild-type (WR)
Vaccinia Viruses under Different Doxycycline C
Concentrations
oncentrations.
Doxycycline

Average Plaque Radius (µm)a

Concentration

a

(ng/ml)

WR

viA3L

viA6L

viA7L

viD6R

viE8R

viF17R

1000

645.4

563.3

628.2

559.9

566.4

650.4

242.7

100

616.9

591.9

645

570.9

628.4

626.1

281.1

10

627.1

579

593.5

590

559.5

627.3

AB

1

641.5

611.6

AB

216.2

320.1

603.8

AB

0

653.1

582.4

AB

AB

AB

554.2

AB

AB = abortive infection.

Figure 4-11.. The Effect of Doxycycline C
Concentration on Plaque Size
ize. The effect of
doxycycline concentration on plaque radius is depicted. BS-C-1
1 cells were infected with
40 PFU/well of virus and allowed to grow in the presence of 0, 1, 10, 100, or 1000 ng/ml
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doxycycline
line for 40 h. At 40 h plaque sizes were measured. Error bars = SEM. *** = p <
0.0001 (paired t-test).

4.3.c. Effect
ct of Doxycycline, Tetracycline, and Anhydrotetracycline on Plaque Size:
No significant difference
differences in the size of plaques were observed among the
different recombinant viruses and WR grown in the presence of 1 µg/ml doxycycline,
tetracycline, or anhydrotetracycline (Figure 4-12).

Figure 4-12. The Effect of T
Tetracyclines (1 µg/ml) on Plaque Size. The effect of
different tetracyclines on plaque radius is depicted. BS
BS-C-1
1 cells were infected with 20
PFU/well of the virus and allowed to grow in tthe
he presence of doxycycline (Dox),
tetracyclinee (Tet), anhydrotetracycline (At
(Atc) (1 µg/ml), or no tetracyclines (Tcs). No
significant differencess were observed among the different tetracyclines. Error bars =
SEM.
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4.3.d. Viral Titers with Varying Doxycycline Concentrations:
With the exception of viD6R, the viral titers obtained 48 h after infection of BSC-1 cells at an MOI of 0.01 in the presence of varying doxycycline concentrations
reflected the plaque sizes that were observed in the single plaque analysis (Figures 4-13
and 4-14). As expected, WR, viA3L, and viE8R showed no dependence on doxycycline
for viral replication, while the titers of viA6L, viA7L, and viF17R were dependent on
doxycycline. Recombinant viA6L had a high titer for 1000, 100, and 10 ng/ml
doxycycline, which dropped rapidly from 8.5 x 106 PFU/ml at 10 ng/ml to 40 PFU/ml at
1 ng/ml doxycycline and remained close to that level at 0 ng/ml doxycycline. viA7L
showed a more gradual decrease in titer. The titer dropped from 7.2 x 106 PFU/ml at 10
ng/ml doxycycline to 1.9 x 104 PFU/ml at 1 ng/ml and finally to 0 PFU/ml in the absence
of doxycycline. The results for viA6L and viA7L mimic what was seen when observing
plaque size.
The titers of viD6R did not follow the observation of plaque size. When
measuring plaque size, no plaques were seen in the absence of doxycycline, however the
titer of viD6R at 0 ng/ml was 1.05 x 105 PFU/ml, much higher than that observed for
viA7L or viA6L (both of which also did not produce plaques in the absence of
doxycycline). The attenuation of viF17R was also apparent in the titers. Although no
viral plaques were observed at 10, 1, or 0 ng/ml doxycycline, the viral titers at 10 and 1
ng/ml doxycycline were increased in comparison to the absence of doxycycline.

63

Figure 4-13.. The Effect of D
Doxycycline Concentration on Viral Titer
iters. BS-C-1 cells
in 12 well plates were infected at an MOI of 0.01 for 1 h and either collected immediately
(Initial Titer) or allowed to grow in the presence of 0, 1, 10
10,, 100, or 1000 ng/ml
doxycycline (Dox) for 48 h. Intracellular virus was processed and titered.
tered. Error Bars =
SD.

Figure 4-14.. The Effect of D
Doxycycline Concentration on Viral Titer
iters. BS-C-1 cells
in 12 well plates were infected at an MOI of 0.01 for 1 h and either collected immediately
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(Initial Titer) or allowed to grow in the presence of 0, 1, 10, 100, or 1000 ng/ml
doxycycline (Dox) for 48 h. Intracellular virus was processed and titered. Fold change
was calculated as the end titer (48 h) compared to the initial (input) titer (0 h).

4.4. DISCUSSION
Both viA3L and viE8R display little or no dependence on the presence of
doxycyline for replication. This result was unexpected as there is evidence of both genes
being critical to viral replication. Both viA3L and viE8R utilize their natural promoters
with the operator sequence inserted prior to translational start site of the essential gene.
The exact location of the promoter sequences for both A3L and E8R are unknown and the
operators may have been inserted in a less than ideal location, causing the gene to be
insufficiently repressed.
The recombinant viF17R was attenuated; replication even in the presence of 1
µg/ml doxycycline was very low compared to all other recombinants and WR. This
effect was seen previously using the lac operon system to control F17R gene expression
(Zhang and Moss, 1991a). In the lac inducible F17R virus the intergenic region of F17R
was not modified except to insert the operator sequence. When creating the viF17R
recombinant, the intergenic region was split at the end of the F17R promoter by the
inserted genetic elements. This left only 34 bp of the intergenic region for the F16L
promoter, if the entire F16L promoter was not located within the 34 bp, it may have
affected the expression of F16L. In previous studies F16L was found to be nonessential
to viral replication in cell culture and this modification to viF17R should not have
decreased viral replication (Senkevich, et al., 2011). In addition, the viF17R gene
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product, p11, may be required in such high amounts that any modification of this strong
late promoter decreases transcription, causing viral replication to also be reduced.
Although viF17R plaque formation is prevented even when 10 ng/mL of
doxycycline is present, the inability of the virus to replicate at levels comparable to WR
even at high doxycycline concentrations makes this recombinant a less than ideal vaccine
candidate. The low rate of replication would cause the vaccine to be attenuated and to
produce an inferior immune response compared to a non-attenuated recombinant.
The recombinant viA6L replicated at levels similar to WR at 1000, 100, and 10
ng/ml of doxycycline. No replication was seen at 1 ng/ml doxycycline. These growth
characteristics are highly desirable for a doxycycline dependent vaccine. This is the first
successful VACV containing an inducible A6L gene. Thus, the viA6L recombinant may
also be useful in clarifying the specific role of this gene. The arrangement of genomic
elements used for this system is unique in that all elements were inserted into the
intergenic region of the gene, this did not require moving the gene of interest to a
different location within the genome, as is frequently done when using the lac operon
system. Recombinant VACV encoding an inducible viA6L gene had previously been
attempted using the lac operon. However, replacing the A6L promoter with an inducible
promoter or inserting an inducible copy of the A6L gene and replacing the A6L gene with
a GFP cassette both failed to generate an inducible A6L mutant (Meng, et al., 2007). The
replacement of the A6L gene with a GFP cassette may have failed to produce a viable
recombinant because removing the A6L gene also removes the last 4 bp of the A5R gene
(RNA polymerase 19kDa subunit). It is unknown why replacing the A6L promoter with
an inducible promoter also failed to generate an inducible mutant. It is possible that the
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gene was unable to be induced to a high enough level to meet the requirement of A6L
using the lac operon system (Meng, et al., 2007).
The recombinant viA7L is also dependent on doxycycline for viral replication.
This virus was able to replicate at 1000, 100, 10, and 1 ng/ml doxycycline, but was
unable to replicate in the absence of doxycycline. Although viA7L was able to replicate
in the presence of only 1 ng/ml doxycycline, its replication was greatly reduced compared
to the higher doxycycline concentrations. An inducible A7L mutant, previously
generated using the lac operon system, was shown to replicate at levels lower than WR
(Hu, et al., 1998). Our viA7L recombinant appears to replicate at levels much closer to
WR than the lac operon mutant previously generated. This may be due to the different
operon systems used and differences in the genetic setup of the viruses. In the lac operon
mutant, the A7L gene is moved to the HA (non-essential) region of the VACV genome
and placed under the control of a T7lacO promoter and the original A7L gene is replaced
by a neomycin resistance gene. A T7 RNA polymerase gene is inserted into VACV in a
non-essential region (TK region) under the control of a P11lacO promoter. This setup
has two lacO-regulated steps, the IPTG dependent transcription of the T7 RNA
polymerase and the IPTG/T7 RNA polymerase dependent transcription of A7L. The
system used to make our recombinants only involves one tetO-regulated step and does
not involve changing the location of the essential genes, the combination of which
appears to allow the viA7L recombinant to replicate at levels close to WR.
Plaque size does not necessarily correlate to viral replication. While plaque size
is a good correlate for some of the recombinants, it is not true for all recombinants. The
recombinant viD6R, similar to viA7L, formed plaques in the presence of 1000, 100, 10,
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or 1 ng/ml doxycycline, although at 1 ng/ml doxycycline plaques were significantly
smaller. Interestingly, viD6R was unable to produce plaques in the absence of
doxycycline, but the virus titer of viD6R in the absence of doxycycline did increase
(compared to the initial or input titer), although it was still severely reduced compared to
viD6R grown in the presence of doxycycline. These results are similar to those generated
using the lac operon system to control the A7L gene. In the absence of inducer (IPTG) no
plaques formed but the virus titer did increase slightly (Hu, et al., 1996).
Tetracyclines are a class of broad spectrum antibiotics. This class includes
naturally occurring antibiotics such as tetracycline, and synthetic tetracyclines such as
doxycyclines. Three different tetracyclines (tetracycline, doxycycline, and
anhydrotetracycline) were tested for their effect on viral replication of the recombinants.
Typically tetracycline or doxycycline are used as inducers of tet operon systems.
Anhydrotetracycline is known to bind TetR with 35-fold higher affinity than tetracycline
(Degenkolb, et al., 1991). Viruses treated with different tetracyclines (doxycycline,
tetracycline, and anhydrotetracycline) at a concentration of 1 µg/ml all produced plaques
of similar size. While this is strongly indicative that the different tetracyclines do not
have an effect on viral replication, this cannot be definitively concluded without the
testing of viral titers.
The observation that anhydrotetracycline does not increase the plaque size of the
recombinant viruses in comparison to equal concentrations of doxycycline suggests that 1
µg/ml of doxycycline is sufficient to induce maximum expression levels of the essential
gene products and that the apparent attenuation of viF17R is not due to insufficient levels
of inducer.
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The goal of this research was to develop recombinant VACVs in which viral
replication can be controlled through the addition/removal of tetracyclines. By placing
the A6L, A7L, D6R, and F17R genes under the control of the tet operon, inducible viruses
were generated. Each recombinant responds uniquely to doxycycline. Based on the
current analysis of the recombinants the viA6L virus appears to have the most desirable
growth characteristics for VACV vectors. The ability of viA6L to replicate at relatively
low doxycycline concentrations (10 ng/ml) at a rate similar to wild type would allow the
antibiotic dose given with the vaccine to be kept at a low and safe level for the vaccine
recipient. The abrupt cease of viral replication between 10 ng/mL and 1 ng/mL that
viA6L displays is also a desirable trait in a doxycycline dependent vaccine. If the
vaccine can be induced with a low dose of doxycycline, when treatment is stopped the
doxycyline concentration within the body should fall to the critical concentration quickly,
rapidly stopping virus replication. Similarly, viA7L is also a good vaccine candidate;
however, this virus did replicate at reduced levels at 1 ng/ml doxycycline. For replication
to be induced at wild-type levels, 10 ng/ml doxycycline had to be used. This suggests
that for a good take to occur upon vaccination, viA7L would require a dose of
doxycycline similar to A6L. However, viral replication could be more difficult to stop,
as 1 ng/ml doxycycline would be sufficient to induce the replication of viA7L. If an
adverse event occurs after vaccination once doxycycline treatment is stopped, the level
within the body would have to decrease to below 1 ng/ml (rather than to below 10 ng/ml
for viA6L) to stop viral replication and the adverse event.
The recombinant viD6R appears to be a good vaccine candidate based on the
plaque size assays, which show no evidence of viral replication in the absence of
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doxycycline. However, the viral titers of viD6R do increase even in the absence of
doxycycline, raising the question of whether this gene would be ideal for vaccine and
therapy vectors.
While viF17R was inducible by tetracyclines, it appears to be attenuated which is
not ideal for smallpox vaccination. This recombinant was unable to replicate at levels
similar to wild type even in the presence of high levels of inducer. Recombinant viA3L
and viE8R were not dependent on tetracyclines for replication, and in their current state
are not good vaccine vector candidates. However, this does not indicate that these genes
may not be useful for controlling VACV replication. There is strong evidence suggesting
that both viA3L and viE8R are essential to VACV replication. As mentioned before, the
tetO sequences may have been inserted in a non-ideal location, allowing leaky or full
expression of the gene. It would be interesting to test whether viral replication would be
controlled if the Pi11 promoter was used in place of the natural promoters.
This work also suggests that more knowledge is needed about VACV promoters
to be able to utilize natural VACV promoters in the control of gene expression. In this
research three natural promoters and three Pi11 promoters were used to control gene
expression. All of the viruses that utilized the Pi11 promoters were successful in
producing tetracycline dependent recombinants (viA6L, viA7L, viF17R), whereas only
one of the viruses that utilized a natural promoter with a tetO sequence was inducible
(viD6R). This may suggest that incorporation of the tetO sequence after the TAAATA
initiator may not be ideal for every late VACV promoter or that unrecognized sequences
within the promoters are acting as initiator sequences.
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DISCUSSION AND FUTURE DIRECTIONS
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Four successful inducible recombinant VACVs were generated (viA6L, viA7L,
viD6R, and viF17R) that have many potential uses. The same strategy could be used for
the development of safer, new generation smallpox vaccines, replacing ACAM2000.
They could also be used for the development of new generation viral vectors for both
human and animal vaccines, and for oncolytic vectors. They would provide a safety
mechanism that would benefit not only the recipients of the vaccine or therapy, but also
personnel administering the vectors (e.g., vaccinators) and contacts of the
vaccine/therapy recipients.
Another important potential use of the inducible VACVs would be to replace the
TetR with a reverse TetR gene, thus creating a repressible VACV. Mutagenesis studies
have shown that the response of the TetR repressor can be reversed, causing TetR to act
as an inducible repressor. A variety of single and multiple mutations in the tetR gene are
able to produce this phenotype. The reverse form of the protein, revTetR, is only able to
bind to the operator sequence and block transcription in the presence of tetracyclines
(Gossen, et al., 1995, Resch, et al., 2008, Scholz, et al., 2004). While different
tetracyclines can be used with the TetR repressor, the effect of tetracyclines on revTetR
varies greatly (Gossen, et al., 1995). The revTetR repressible system is currently being
adapted to the VACV system (Titong and Verardi, unpublished data).
The repressible VACVs would have similar applications as the inducible VACVs,
but instead of requiring tetracyclines for viral growth, tetracyclines would stop viral
replication. A repressible system would be especially beneficial in animal vaccines, such
as the oral rabies vaccine. The oral rabies vaccine, which is composed of a VACV
vector, is used across the United States to vaccinate wildlife against rabies. There are
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currently 16 states distributing the vaccines in baits for wildlife (Slate, et al., 2009). The
baits are composed of a plastic packet containing the vaccine and coated in fishmeal to
attract animals. Once an animal bites the bait the packet of vaccine is broken and the
vaccine leaks into the mouth, resulting in viral replication and immunization of the
animal (Slate, et al., 2005). Although oral rabies vaccination programs are careful of
where baits are dropped, inevitably people come in contact with the baits and the VACV
vaccine vector they carry. One such incident occurred in Pennsylvania in 2009 when a
dog brought its owner a ruptured vaccine bait. The owner had cuts on her hands and
developed a VACV infection from handling the bait. As the owner was on
immunosuppressive medication for inflammatory bowel disease, treatment with VIGIV
(Vaccinia Immune Globulin Intravenous) and investigational antiviral agents were
required to clear the VACV infection. However, she was not able to remain off her
immunosuppressive medication for an extended period, making her treatment difficult
(Centers for Disease Control and Prevention, 2009). If a repressible VACV had been
used in the rabies vaccine the woman could have been treated with tetracyclines to stop
the VACV infection and may not have needed to be removed from her medication.
The inducible VACV generated have many practical uses and will hopefully
allow VACV to be utilized more frequently as a vector to develop life-saving vaccines
and therapeutics.
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